Biodesix Using VeriStrat to Evaluate Kadmon's Tyrosine Kinase Inhibitor | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biodesix today announced it is collaborating with biopharma Kadmon to evaluate the use of Biodesix's test for a non-small cell lung cancer study for Kadmon's reversible tyrosine kinase inhibitor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.